Originally published In Press as doi:10.1074/jbc.M201812200 on April 8, 2002
J. Biol. Chem., Vol. 277, Issue 25, 22147-22155, June 21, 2002
Identification of LBM180, a Lamellar Body Limiting Membrane
Protein of Alveolar Type II Cells, as the ABC Transporter Protein
ABCA3*
Surafel
Mulugeta
§,
Joseph M.
Gray¶,
Kathleen L.
Notarfrancesco
,
Linda W.
Gonzales
,
Michael
Koval
,
Sheldon I.
Feinstein
,
Philip L.
Ballard
,
Aron B.
Fisher
, and
Henry
Shuman
**
From the
Institute for Environmental Medicine,
University of Pennsylvania School of Medicine and
Division
of Neonatology, Department of Pediatrics, The Children's Hospital of
Philadelphia, University of Pennsylvania,
Philadelphia, Pennsylvania 19104
Received for publication, February 22, 2002, and in revised form, March 29, 2002
 |
ABSTRACT |
Lamellar bodies are the specialized
secretory organelles of alveolar type II (ATII) epithelial cells
through which the cell packages pulmonary surfactant and regulates its
secretion. Surfactant within lamellar bodies is densely packed as
circular arrays of lipid membranes and appears to be the product of
several trafficking and biosynthetic processes. To elucidate these
processes, we reported previously on the generation of a monoclonal
antibody (3C9) that recognizes a unique protein of the lamellar body
membrane of 180 kDa, which we named LBM180. We report that mass
spectrometry of the protein precipitated by this antibody generated a
partial sequence that is identical to the ATP-binding cassette protein, ABCA3. Homology analysis of partial sequences suggests that this protein is highly conserved among species. The ABCA3 gene transcript was found in cell lines of human lung origin, in ATII cells of human,
rat, and mouse, as well as different tissues of rat, but the highest
expression of ABCA3 was observed in ATII cells. Expression of this
transcript was at its maximum prior to birth, and hormonal induction of
ABCA3 transcript was observed in human fetal lung at the same time as
other surfactant protein transcripts were induced, suggesting that
ABCA3 is developmentally regulated. Molecular and biochemical studies
show that ABCA3 is targeted to vesicle membranes and is found in the
limiting membrane of lamellar bodies. Because ABCA3 is a member of a
subfamily of ABC transporters that are predominantly known to be
involved in the regulation of lipid transport and membrane trafficking,
we speculate that this protein may play a key role in lipid
organization during the formation of lamellar bodies.
 |
INTRODUCTION |
Pulmonary surfactant is a complex mixture of phospholipids and
proteins that functions to prevent atelectasis by reducing alveolar
surface tension at low lung volumes (1, 2). Surfactant consists
predominantly of phospholipids, synthesized by alveolar type II
(ATII)1 cells, and several
unique proteins. Surfactant protein (SP)-A, SP-B, SP-C, and SP-D are
synthesized by ATII cells, but with the exception of SP-C, they are
also produced by other cells (3, 4). The alveolar surfactant pool size
appears to be controlled primarily by ATII cells that regulate both
secretion to and re-uptake from the alveolar space. Prior to secretion,
surfactant lipids along with surfactant proteins are stored in lamellar
bodies as densely packed lamellae and are secreted into the alveolar
lumen by regulated exocytosis (5). The average ATII cell normally contains 150 ± 30 lamellar bodies (6) with an in vivo
basal secretion rate of ~15 lamellar bodies per h in rat lung (7). ATII cells also endocytose surfactant from the alveolar space, some of
which is recycled to lamellar bodies (8-12) and the remainder is
degraded (9). Because of its central role in lung surfactant turnover,
we have focused on the assembly of this organelle and the proteins that
distinguish it from other secretory organelles.
Lamellar bodies appear to be at the intersection of several membrane
trafficking and vesicle sorting pathways. Surfactant lipids and
proteins are targeted to lamellar bodies from both the secretory and
endocytic pathways. SP-B and SP-C are delivered to lamellar bodies from
the endoplasmic reticulum via the secretory pathway (13, 14), whereas
SP-A is secreted to the airspace and subsequently internalized and
trafficked to lamellar bodies via clathrin-coated pits through early
and late endosomes (12, 15). Newly synthesized lipids, such as
phosphatidylcholine, are also delivered to the lamellar body from the
endoplasmic reticulum via the secretory pathway (16-18). Surfactant
lipids are internalized and delivered to lamellar bodies by two
pathways, one clathrin-dependent and another
clathrin-independent but actin-dependent (19).
Proteins essential for the formation of lamellar bodies have not been
completely defined. SP-B appears to be one of the key proteins
necessary for the proper organization of lamellar bodies. Newborns with
hereditary SP-B deficiency have poorly formed lamellar bodies and
abnormal surfactant (20, 21). Similar abnormalities have been
demonstrated in SP-B-deficient mice (22). However, other contributing
factors must also exist because loss of lamellar bodies or poorly
formed lamellar bodies have been observed in abnormalities associated
with refractory neonatal respiratory failure and congenital alveolar
proteinosis where SP-B appears normal (23, 24).
In an effort to understand the formation and organization of lamellar
bodies, we began the process of identifying proteins that are uniquely
expressed in this organelle. In our previous report (25), we described
the generation of a panel of 30 antibodies against the limiting
membrane of lamellar bodies isolated from rat ATII cells. One of these
antibodies, monoclonal antibody (mAb) 3C9, labels lamellar bodies of
ATII cells with high specificity. Further characterization revealed
that the antigen is an integral membrane protein with a molecular mass
of 180 kDa, which we named LBM180. The present study identifies LBM180
as ABCA3, a member of ATP-binding cassette (ABC) transporter family,
and characterizes temporal, spatial, and regulated expression.
ABC transporters represent the largest family of transmembrane
proteins, and its members have been found in every organism examined so
far (26). These proteins bind ATP and use the energy of its hydrolysis
to drive the transport of various substrates across cell membranes
(27-29). The human ABC proteins are classified into subfamilies that
include the ABCA subfamily of lipid transporters, multidrug
resistance/transmembrane-associated proteins, adrenoleukodystrophy proteins, and the cystic fibrosis transmembrane conductance regulator (30). They transport a wide variety of substrates including lipids,
ions, amino acids, peptides, sugars, vitamins, steroid hormones, and
toxic compounds (30). Their distinguishing features are two nucleotide
binding domains with conserved Walker A and B motifs, both involved in
ATP binding (present in many other ATP-utilizing proteins), one
conserved sequence diagnostic to the ABC unit called the "ABC
signature" located between the Walker A and B sequences, and 12 membrane-spanning helices (31). Substrate specificity appears to be
determined by the transmembrane domains, whereas coupling of the two
nucleotide binding domains provides the energy required for transport.
ABCA3 was originally cloned from a human medullary thyroid carcinoma
cell line, and in humans, its message is expressed most highly in lung
(32, 33). Recently, Yamano et al. (34) cloned ABCA3 from
human lung and showed, by immunohistochemical analyses, that ABCA3 is
an ATII cell lamellar body membrane protein. They also demonstrated
that ABCA3 protein had a molecular mass of 150 kDa in human lung but
when expressed in HEK 293 cells, the protein had a molecular mass of
180 kDa. ABCA3 is a member of the ABCA subfamily of transporters and
shares high homology with ABCA1. ABCA1, along with a number of other
transporters belonging to the same subfamily, is believed to
participate in the regulation of cellular lipid transport (35, 36).
Consequently Yamano et al. (34) suggested that ABCA3 may
function as a transporter of the phospholipid components of pulmonary surfactant.
We report that ABCA3 was identified by immunoprecipitation from
purified lamellar bodies of rat lung with mAb 3C9 confirming the
previous results in another species. The ABCA3 transcript was found in
cell lines of human lung origin, in human, rat, and mouse ATII cells
with the highest expression of ABCA3 mRNA observed in ATII cells.
The transcript was also observed in significant quantities in several
non-lung tissues in rats. The protein appears to be developmentally and
hormonally regulated with a pattern similar to other surfactant-related
proteins. Antibodies generated against peptides derived from the human
ABCA3 sequence recognized a 180-kDa lamellar body protein in human
fetal ATII cells. These together with previous results establish the
presence of a preferentially expressed and developmentally regulated
ABC transporter in lamellar bodies of ATII cell. Preliminary reports of
this work have been published as abstracts (37, 38).
 |
EXPERIMENTAL PROCEDURES |
DNA Constructs--
The human full-length ABCA3 cDNA was
prepared by amplifying three overlapping ~2-kb segments of cDNA
by reverse transcription (RT)-PCR method according to the
manufacturer's recommendations (Advantage,
CLONTECH, Palo Alto, CA). Total RNA of cells and
tissues was transcribed by enzymatic reverse transcription followed by PCR amplification. The three segments chosen had unique restriction sites in their overlapping regions, namely BamHI,
DraIII, and BsmI, and each were ligated into a
TOPO-TA vector (pCR 2.1-TOPO, Invitrogen, Carlsbad, CA). Following
amplification of the plasmids in competent bacterial cells
(Invitrogen), the three segments were cut with the aforementioned
restriction enzymes and were ligated to each other. The primers (primer
nucleotide numbering is based on the data base, from the National
Center for Biotechnology (NCBI), data accession number NM001089, of
the human ABCA3) generated for these segments are as follows:
forward primers, 5'-GACCACCTACTTCTCTAGCAGCACTGGGCG-3', corresponding to nucleotides
47 to
18 from the START (ATG)
codon; 5'-GGGCCATCTGGGATCTTCTTC-3', corresponding to nucleotides
2661-2681; and 5'-GAGGGGGGCGGCTTTAATGAGCGGTGCCTTGTG-3', corresponding
to nucleotides 3602-3634; reverse primers,
5'-GGTAGGTCGAGGGACGGGACGTCATGGTCGTGC-3', corresponding to
nucleotides 3111-3143; 5'-CTGCACGCACGGAAGTGC-3', corresponding
to nucleotides 4061-4078; and
5'-CGGGAGTACGGGTCCTACGTCGTAGCGTAGAGG-3', corresponding to
nucleotides 5841-5873. The 310-bp ABCA3 cDNAs of cells and tissues
were prepared by RT-PCR using the following primers: forward primer,
5'-GCGAGTGCGCGGCTTTTCCCTCCGAGAAGGACTT-3', corresponding to nucleotides
874-906; and reverse primer, 5'-CCGGATGTACCCAGGTTCTCCGCCATCAGGGGA-3' (complement to bases corresponding to the peptide SPDGGEPGYIR), corresponding to nucleotides 1151-1183. EGFP/ABCA3 cDNA
fusion constructs were generated by ligating the full-length hABCA3
cDNA into a pEGFP-N1 amino-terminal protein fusion vector
(CLONTECH) after removing the STOP (TGA) codon of
ABCA3 by cutting at an internal BglI restriction site
located near the STOP site of ABCA3. All resultant plasmids were
transformed into competent bacterial cells (Invitrogen) for amplification.
Antibody Generation--
Two peptides from putative antigenic
regions of the deduced amino acid sequence of human ABCA3 were
synthesized and used to immunize rabbits. These regions of the protein
have no homologies to any other proteins in the NCBI data base and no
homologies to any known rabbit sequence. The peptides prepared were
CQEKERRLKEYM (ABCA3 luminal loop) and CGKPRAVAGKE (ABCA3 cytosolic
domain) producing antibody 1 and antibody 2, respectively.
Immunoblot Analysis--
Protein samples were separated with
SDS-PAGE under reducing conditions. Samples were solubilized in sample
buffer (125 mM Tris/HCl, 0.32 M sucrose, 2%
(w/v) SDS, 65 mM dithiothreitol, and 0.001% bromphenol
blue, pH 6.8) at room temperature. The separated proteins were
transferred electrophoretically onto nitrocellulose membranes (BA83,
0.32-µm pore size; Schleicher & Schuell) overnight at 20 mA in
transfer buffer (12.5 mM Tris, pH 8.3, 96 mM
glycine, 0.1% SDS, 15% (v/v) methanol, pH 8.0). Protein-binding sites
were blocked by TBS containing 2-5% non-fat dry milk for 60 min at room temperature. The membrane was then incubated with primary antibody
in TBS/milk solution for 2 h at room temperature. After three
15-min washes with TBS, the nitrocellulose was incubated for another 60 min at room temperature in TBS/milk solution containing horseradish
peroxidase-conjugated anti-mouse, -rat, or, -rabbit IgG (1:2000 normal
dilution). Blots were visualized by enhanced chemiluminescence (ECL
System, Amersham Biosciences).
Northern Blot Analysis--
Total RNA was prepared from cells
and tissues using RNeasy Mini Kit (Qiagen, Valencia, CA) and separated
by formaldehyde-agarose gel electrophoresis and transferred to
nitrocellulose membrane (BA83, 0.32-µm pore size; Schleicher & Schuell). Blots were prehybridized in 50 mM sodium
phosphate, pH 6.5, 5× SSC, 5× Denhardt's, 50% formamide, 0.1% SDS,
and 100 µg/ml salmon sperm DNA for 4 h at 42 °C.
Hybridization was carried out overnight in the same buffer containing
106 cpm/ml of a 32P-labeled 310-bp ABCA3
cDNA fragment. The filters were washed twice for 15 min in 1× SSC,
0.1% SDS at room temperature and then twice for 20 min in 0.2× SSC,
0.1% SDS at 55 °C, and the filters were exposed to a
PhosphorImaging screen for 24-72 h. The intensities of signals on the
autoradiogram were quantified on a PhosphorImager using the Quantity
One computer software (Bio-Rad). To correct for RNA loading, the
obtained signals were normalized with the densitometer quantified
ethidium bromide-stained 28 S or 18 S bands.
Developmental Study--
Animal protocols were reviewed and
authorized by the Institutional Animal Care and Use Committees of both
the University of Pennsylvania and The Children's Hospital of
Philadelphia (Philadelphia, PA). "Timed-pregnant" Wistar rats
(mating day = Gestational Day (GD) 1, term = GD 22) and
newborn Wistar rats were used. Pregnant rats were delivered by
Caesarian section at GD 17, 19, and 21 or were allowed to deliver
naturally. Neonatal rats were designated to be 1-day-old postnatal day
(PD) 1. PD 1, 4, 7, 14, and 16-week-old (as adult) rats were subjected
to study. All animals were sacrificed by cutting the abdominal aorta
after a surgical level (toe pinch) of anesthesia was induced with
intraperitoneal injection of pentobarbital (<50 mg/kg).
Immunofluorescence--
Cells in culture were fixed in 2%
paraformaldehyde for 30 min, permeabilized with 0.3% Triton X-100, and
washed. Lung tissues were cryosectioned (5-8 µm), and sections
adhered to slides. The slides were incubated in NaBH4 to
reduce tissue autofluorescence, permeabilized with Triton X-100, and
washed in phosphate-buffered saline (PBS) (137 mM NaCl, 10 mM Na2HPO4, 2.7 mM KCl,
1.8 mM KH2PO4, pH 7.4). After
washing, cells or sections were blocked with 5% normal goat serum,
washed with PBS, incubated with primary antibody for 2 h at room
temperature, washed, and incubated with fluorescent Texas
Red-conjugated secondary IgG for 1 h. Specimens were mounted in
Mowiol and examined by fluorescence microscopy.
Antigen Retrieval--
Antigen retrieval by anti-ABCA3 was
carried out as described previously (39). Briefly, cultured cells on
glass cover slips were rinsed in serum-free medium, fixed with 4%
paraformaldehyde, and washed with PBS. Cells were permeabilized with
0.3% Triton X-100, washed with PBS, and treated with 1% SDS for 5 min
before continuing with immunofluorescence described above.
Microscopy--
Samples were observed with inverted Nikon
fluorescence microscopes equipped with either a cooled CCD camera and
MetaMorph image analysis software (Universal Imaging, West
Chester, PA) or Bio-Rad Microradiance 2000 confocal
attachment (Bio-Rad).
Explant Culture--
Human fetal lungs were obtained from
14- to 22-week gestation therapeutic abortions under protocols
approved by the Committee on Human Research at The Children's
Hospital of Philadelphia. Fetal lung parenchyma was minced
into 1-mm3 pieces and placed in organ culture, as described
previously (40). Briefly, tissue pieces were distributed in two
parallel strips on 60-mm culture dishes placed on a platform that rocks
(3 oscillations/min) to expose the explants alternately to serum-free
Waymouth medium (2 ml/dish) or an atmosphere of 95% air, 5%
CO2. The explants were maintained for 1-5 days in medium
without (control) or with dexamethasone (Dex, 10 nM)
8-bromo-cAMP (0.1 mM) plus isobutylmethylxanthine (IBMX,
0.1 mM), or both Dex and the cAMP agents. IBMX was added to
all explants treated with 8-bromo-cAMP to maintain tissue cAMP levels.
Fresh medium was added every 24 h. Tissue explants were harvested
either before culture (preculture) or at various times during culture.
Hormones were added to the medium of treated explants after 24 h
of culture. The hormone concentrations used maximally stimulated
phosphatidylcholine synthesis in the explants as described previously
(41).
Isolation of Primary Cultures of ATII Cells from Adult Rats Using
Elastase--
ATII cells were isolated using elastase essentially
according to the method of Dobbs and Williams (42). The lungs of
anesthetized Sprague-Dawley rats were perfused via the pulmonary artery
and excised. The lungs were lavaged with elastase solution, chopped, placed in a flask, and shaken. The tissue was filtered through graded
filters; the cells were centrifuged and then resuspended in minimal
essential media without serum. The cells were "panned" on IgG
plates to remove the macrophages and lymphocytes and replated in
minimal essential media with 10% fetal calf serum. Every preparation of isolated ATII cells was identified by morphology and by staining of
lamellar bodies with phosphine 3R (Pfaltz & Bauer, Inc.) or Nile Red
(Sigma). Viability was monitored by exclusion of trypan blue. Rare
cultures with more than l0% macrophages were discarded.
Isolation of ATII Precursor Cells and in Vitro
Differentiation--
Fetal ATII precursor cells were isolated from
human (14- to 22-week gestational age) lung using collagenase-trypsin
digestion and differential adhesion to remove fibroblasts and plated on coverslips coated with extracellular matrix produced by Madin-Darby canine kidney cells (43, 44). Final cultures contained fewer than 10%
fibroblasts. Cells were cultured in Waymouth's medium in 35-mm dishes.
The following day, Dex (10 nM), cAMP (0.1 mM), and IBMX (0.1 mM) (DCI) were added to the media for the
remainder of the culture period. Media were changed daily, and cells
were studied at days 1 and 4 of culture. Fetal human lung treatment results in the differentiation of the precursor cells into ATII-like cells that contain lamellar bodies, express SP-A, -B, and -C
mRNAs, process SP-B and -C proprotein to mature forms, and have
regulated exocytosis of phospholipids (45).
Preparation of Lamellar Bodies and Lamellar Body Membrane from
Lung--
Lamellar bodies were isolated from rat lungs cleared of
blood or from human lung explants using upward flotation on a sucrose density gradient, as described previously (46). The lamellar body
fraction was collected between 0.35 and 0.50 M sucrose and pelleted in 0.20 M sucrose by centrifugation at 20,000 × g for 20 min. To isolate lamellar body membranes, the
freshly isolated lamellar body fraction was suspended in hypotonic
solution (10 mM Tris-HCl, 50 mM sucrose, pH
7.2) along with protease inhibitors (2 mM
phenylmethylsulfonyl fluoride, 2 mg/ml
N-acetyl-leucyl-leucyl-norleucinal, 5 mg/ml leupeptin, 10 mg/ml aprotinin, 10 mg/ml pepstatin A) and set on ice for 3 h or
overnight at 4 °C. The suspension was loaded on a cushion of 0.50 M sucrose and centrifuged for 1 h at 100,000 × g using a swinging bucket rotor. The lamellar body membrane fraction was recovered from the pellet, whereas the lamellar body content fraction was recovered at the interface of buffer and 0.50 M sucrose.
DNA Microarray Analysis--
Total RNA from day 4 control and
hormone (DCI)-treated cells was used to prepare cDNAs and
biotin-labeled cRNAs according to the protocol provided by the
manufacturer (Affymetrix, Santa Clara, CA). We performed hybridization
with microarray chip 9000183 (Affymetrix), which contains probes for
~5,600 human genes, and analyzed data using Affymetrix software. Two
separate experiments were performed with cells from lungs of 14- and
17-week gestation.
Immunoprecipitation--
Immunoprecipitation was carried out, as
described previously (47), with slight modifications. Lamellar body
membrane fraction was resuspended in ice-cold PBS. To reduce
nonspecific binding, the lamellar body membrane suspension was
incubated with-end-over-end rotation for 90 min at 4 °C with 10 µl
of preimmune serum (normal goat serum, Jackson ImmunoResearch) followed
by 40 µl of protein A-Sepharose (Amersham Biosciences). After
centrifugation, the supernatant was transferred into a clean tube and
incubated with mAb 3C9 on end-to-end rotation for 90 min at 4 °C.
Antibody complex was then precipitated with 50 µl of protein
A-Sepharose by incubation for 90 min at 4 °C with end-over-end
rotation. The immune complex protein A-Sepharose was collected by
centrifugation and washed 4 times with ice-cold lysis buffer (150 mM NaCl, 50 mM Tris-Cl, pH 8.0, 1% Triton
X-100, 1% deoxycholate, 0.1% SDS), and the bound proteins were
solubilized with 25 µl of SDS-PAGE sample buffer (48) (10% glycerol,
5%
-mercaptoethanol, 2.3% SDS, and 0.062 M Tris-HCl,
pH 6.8). The Sepharose beads were removed by centrifugation, and the
proteins were resolved by 10% SDS-PAGE.
Transfection--
Transfection was performed by the FuGENE 6 method (Roche Molecular Biochemicals) according to the manufacturer's
recommendation. 4 µg of pEGFP-N1-tagged ABCA3-containing plasmid was
preincubated with 6 µl of FuGENE 6 in a total volume of 100 ml of
serum-free medium at room temperature for 15-30 min. The complex
mixture was added dropwise to 60-70% confluent cells in a 35-mm dish
containing 3 ml of fresh medium with 10% fetal calf serum. Cells were
incubated at 37 °C for various times, and medium was replaced 3 days
after start of transfection.
Statistics--
Experiments were analyzed by one-way analysis of
variance. All values were expressed as mean ± S.E. All
computations were performed using SigmaStat 2.0 statistical analysis
software (Jandel Corp., Chicago, IL).
 |
RESULTS |
Purification of the Lamellar Body Specific Protein from Lamellar
Body Membranes--
The lamellar body membrane-specific protein LBM180
was identified previously using monoclonal antibody, mAb 3C9 (25). To confirm this finding prior to protein purification, Western blot analysis was repeated on purified lamellar body membrane proteins. Lamellar bodies from rat lungs were purified to near-homogeneity (Fig.
1A), and the membrane fraction
was separated from the intra-organelle contents by osmotic shock
followed by centrifugation. The proteins from the membrane and content
fractions were further separated by SDS-PAGE. Immunoblot with mAb 3C9
revealed a single band at 180 kDa in the membrane fraction and no
labeling in the content fraction (Fig. 1B). To isolate the
immunoreactive protein, immunoprecipitation was performed by incubating
mAb 3C9, linked to Sepharose beads, with rat lamellar body proteins
followed by centrifugation. Proteins bound to the beads were
solubilized in SDS-PAGE running buffer and separated by gel
electrophoresis. Coomassie Blue staining of the gel revealed a band of
180 kDa, along with a lower molecular mass band at 100 kDa (Fig.
1C). A double layer immunoblot of a duplicate gel with mAb
3C9 confirmed the identity of the 180-kDa band with the antigen of mAb
3C9 (Fig. 1D, arrow). The lower band could be a
fragment of the 180-kDa protein (Fig. 1, C and D,
arrowhead). It is also possible that this band is the heavy
chain of mAb 3C9 that is recognized by the secondary antibody. In
parallel Coomassie gels when mAb 3C9 alone was loaded, the heavy chain
of mAb 3C9 that was reduced and solubilized in SDS, but not boiled,
migrated as a 100-kDa band (Fig. 1E, lane 2,
arrowhead). For protein identification, the 180-kDa band of
the Coomassie-stained gel was removed and sequenced by mass
spectrometry. Trypsin digestion of the extracted protein yielded
peptides that were analyzed by a tandem array mass spectrometry. Only
one peptide had an amino acid sequence that did not correspond to
fragments of contaminating IgG. That sequence (SPDGGEPGYIR) was
identical to a portion of the ATP-binding cassette protein, ABCA3.

View larger version (152K):
[in this window]
[in a new window]
|
Fig. 1.
Isolation of a 180-kDa protein with mAb
3C9. A, electron micrograph of rat lung lamellar bodies
purified to homogeneity by sucrose density gradient centrifugation. The
limiting membranes of intact lamellar bodies are shown
(arrows). B, immunoblot with mAb 3C9 showing a
single band at 180 kDa in the membrane fraction (lane 2, arrow) but not in the content fraction (lane 1) of
lamellar body proteins. C, Coomassie-stained gel of
immunoprecipitation products of lamellar body proteins with mAb 3C9
showing supernatant (lane 1) and precipitated products
(lane 2), containing a band at 180 kDa (arrow)
and a band at ~100 kDa (arrowhead). The heavy chain of mAb
3C9 runs at this higher molecular mass of ~100 kDa instead of the
usual ~50 kDa when samples are not boiled before electrophoresis.
D, immunoblot with mAb 3C9 of duplicate gel as in
C showing bands of 180 (arrow) and 100 kDa
(arrowhead) in both supernatant (lane 1) and
precipitated products (lane 2). E, Coomassie
Blue-stained gel of reduced and boiled (lane 1) and reduced
but not boiled (lane 2) pure mAb 3C9 antibody showing the
usual migration of the heavy chain at ~50 kDa (lane 1,
open arrow) and the migration of heavy and light chains at
~100 (lane 2, arrowhead) and ~55 kDa
(lane 2, lower band) respectively.
|
|
Cell and Tissue Distribution and Cross-species Sequence Homology of
ABCA3 by RT-PCR Analysis--
To determine cell and tissue
distribution of ABCA3 mRNA, various cell lines and tissues were
assessed by RT-PCR using human ABCA3 gene-specific
oligonucleotide primers (Fig. 2). A
310-bp PCR product was amplified from mRNA isolated from
human and rat ATII cells and rat and mouse lung total mRNA. Human
adenocarcinoma cell lines A549 and NCI H441 expressed the ABCA3
mRNA as well, although at lower levels, whereas HeLa (a human
cervical epithelial cell line) and rat pancreatic
HC9 cells did not.
RT-PCR results were confirmed by Northern blot, where A549 and H441
cells had much lower expression of ABCA3 message (not shown) than ATII
cells (Fig. 4).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 2.
Cell and tissue specificity of ABCA3
message. Ethidium bromide-stained agarose gel showing
310-bp bands of RT-PCR (25 cycles) products obtained using
ABCA3 gene-specific oligonucleotide primers. The transcript
was visibly amplified from human (h) and rat ATII cells,
lung homogenate from rat (r) and mouse (m), and
A549 and H441 cells but was not detectable in HeLa and HC9
cells.
|
|
The deduced amino acid sequence of the ABCA3 PCR products had high
homology between three species examined (Fig.
3). The human ATII cell sequence is
identical to the previously published (32) ABCA3 cDNA sequence
obtained from human thyroid medullary carcinoma cells. There is
86% identity and 94% positive homology between murine and
human amino acid sequences, whereas the rat is 91% identical and 98%
homologous with the mouse sequence.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
A partial, deduced ABCA3 amino acid sequence
is highly conserved between species. The 310-bp ABCA3
nucleotide transcripts (Fig. 2) of human (h), rat
(r), and mouse (m) were sequenced, and the
deduced amino acid sequences of the 244 nucleotides (310 bases minus 66 bases of primers) were analyzed for homology. Gray shading
indicates a consensus sequence.
|
|
Expression of ABCA3 Transcripts--
Northern blot analysis of
mRNA from rat ATII cells and various rat tissues showed a single
transcript of 6.5 kb (Fig 4A). For all organs, the highest ABCA3 expression was observed in lung and
was consistent with the previously reported level of expression in
human tissues (32). Significant expression of mRNA was also clearly
detected in stomach, intestine, and kidney with lower levels of
expression in thyroid, brain, liver, spleen, heart, testis, and thymus
(Fig. 4B). Unlike the human counterpart (32), expression of
ABCA3 mRNA was not detected in rat pancreas.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 4.
Expression of ABCA3 messages from rat ATII
cells and rat tissues. Total RNA from ATII cells and multiple
tissues of rat were blotted and hybridized with a 310-bp hABCA3
probe. A, representative blot showing 6.5-kb band
(arrow) and the corresponding ethidium bromide-stained 28 S
band (arrowhead). B, the bands were quantified by
PhosphorImage computer system and expressed as arbitrary units by
normalizing the PhosphorImage of each band against its 28 S band.
Results are expressed as mean ± S.E., n = 3.
|
|
Developmental Expression of ABCA3--
Surfactant production is
developmentally regulated during gestation and reaches maximal levels
prior to birth (49-51). To address the question of whether ABCA3 is
induced during lung development, total rat lung RNA was collected on
days 17, 19, and 21 of gestation and days 1, 4, 7, 14 and 16-weeks
postnatal. Northern blot analyses revealed significant increases of
ABCA3 message levels between days 17 and 21 of gestation and then a
decrease after birth to a nadir at approximately day 7 postnatal (Fig.
5). By day 14 postnatal, the message had
returned to ~75% of the adult level of expression.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 5.
Expression of ABCA3 during gestation and
after birth in rats. A, Northern blot of total RNA
collected from Sprague-Dawley rat lung at days 17, 19, and 21 of
gestation (E); postnatal (P) days 1, 4, 7, 14, and at 16 weeks (adult) were hybridized with a 310-bp ABCA3
probe. A representative blot from one of three different experiments
demonstrating hybridized bands at 6.5 kb (arrow) and the
corresponding ethidium bromide-stained 18 S bands
(arrowhead) are shown. B, quantification of the
relative PhosphorImage of each band is normalized against its 18 S
band and subsequently to the relative PhosphorImage of the message
detected in adult rat lung (16 weeks). Results are expressed as
mean ± S.E. *, p < 0.05 versus 16 weeks. , p < 0.01 versus 16 weeks.
|
|
Lung maturation and surfactant production can be accelerated by
corticosteroid hormones (52-54). To evaluate the hormonal
responsiveness of ABCA3, gene array and Northern blot analyses were
utilized for the human fetal lung and alveolar type II cells during
in vitro differentiation in either the absence (control) or
presence of Dex, cAMP, and IBMX (DCI). A Northern blot of fetal lung
explants showed increased (>30-fold) expression with DCI treatment,
whereas day 1 and control explants had nearly background expression
(Fig. 6A). Explants treated
with Dex or cAMP alone also showed increased expression. The increase
was synergistic (>35-fold) with combined hormone treatment (Fig.
6B). Similar results were obtained with microarray gene
expression analysis of ATII cells harvested from 14- and 17-week old
lungs in which DCI greatly increased (44- and 28-fold, respectively)
hABCA3 mRNA expression compared with control cells (Table
I). Overall, compared with the 159 genes induced >2-fold, the hABCA3 mRNA was the seventh most highly
induced gene in differentiating ATII cells.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 6.
Hormonal induction of ABCA3 message during
in vitro differentiation of human fetal explants of
lung and isolated cells. Human fetal explants of 14-week gestation
lung (A) and 22-week gestation ATII progenitor cells
(B) were cultured in the absence (day 1, day 4 control) or
presence of Dex/cAMP/IBMX (DCI). Northern blots of total RNA from each
culture was hybridized with a hABCA3 cDNA probe. A representative
Northern blot demonstrating hybridized bands at 6.5 kb
(arrow) from three different lung explants (A)
and at least three separate ATII cell experiments (B) are
indicated by the arrow, and the corresponding ethidium
bromide-stained 28 S bands (arrowhead) are shown. The bands
were quantified by PhosphorImaging computer system, and arbitrary units
were generated by normalizing the PhosphorImage of each band against
its 28 S band. Results are expressed as mean ± S.E. *,
p < 0.05 versus control. ,
p < 0.01 versus control.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Gene array analysis for hormone induction of ABCA3 and
surfactant-related mRNA
Oligonucleotide chip experiments using RT-PCR to amplify expressed
mRNAs from DCI-induced, 14- and 17-week-old human fetal ATII cells
demonstrate significant increases in ABCA3 expression. Data are fold
increase compared with control and day 4 of culture and are individual
values from two experiments. FAS, fatty-acid synthase.
|
|
Localization of mAb 3C9-positive Protein in the Limiting Membrane
of Lamellar Bodies of Mouse--
To evaluate whether mAb 3C9,
previously shown to recognize a lamellar body membrane protein in rat
ATII cells (25), also recognizes the mouse homologue, lung sections
from mouse and rat were used for immunofluorescence studies. Texas
Red-conjugated mAb 3C9 labeled both tissues in a similar manner (Fig.
7). The antibody appears to label the
limiting membrane of lamellar bodies, as indicated by the ring-like
staining surrounding the lamellar bodies (Fig. 7, A and
B, insets). However, this antibody does not react
with human lung or ATII cells (data not shown).

View larger version (118K):
[in this window]
[in a new window]
|
Fig. 7.
Monoclonal antibody 3C9 recognizes a lamellar
body membrane-specific protein. Mouse (A and
C) and rat (B and D) lungs were fixed
and labeled sequentially with primary mAb 3C9 (mouse anti-rat 1:200)
and secondary (goat anti-mouse IgG Texas Red-conjugated) antibodies.
Staining was visualized by confocal (A) or direct
(B) fluorescence microscopy and phase contrast microscopy
(C and D). Bars, 10 µm.
|
|
Lamellar Body Localization of ABCA3 in ATII Cells--
We
generated two polyclonal antibodies that recognize ABCA3 using
synthetic peptides with amino acid sequences matching putative intracellular (antibody 1) and extracellular regions (antibody 2) of
the human ABCA3 protein. Immunofluorescence and immunoblot analysis
were performed to determine the localization and expression of ABCA3 by
ATII cells using these anti-hABCA3 antibodies. By immunofluorescence,
using an antigen retrieval method, anti-hABCA3 antibody 1 labeled
membranes of human ATII cell organelles (Fig. 8B, arrows), which
was similar to the labeling pattern observed for rat ATII cells with
mAb 3C9 (Fig. 8A). Immunoblot analysis revealed that
anti-hABCA3 antibody 2 recognized a 180-kDa band in protein samples
from a purified lamellar body fraction of human fetal but not rat lung
(Fig. 8E). Neither of these ABCA3 antibodies labeled rat
protein by immunofluorescence (data not shown).

View larger version (83K):
[in this window]
[in a new window]
|
Fig. 8.
Characterization of anti-human ABCA3
antibodies. A, rat ATII cells cultured overnight were
fixed and labeled with mAb 3C9 as described in Fig. 7. B,
progenitor ATII epithelial cells, isolated from 22-week-old human fetal
lung were cultured in the presence of hormones (DCI). After 4 days in
culture, cells were fixed and labeled sequentially with a primary
polyclonal anti-ABCA3 (rabbit anti-human) culture supernatant and
secondary (goat anti-rabbit IgG Texas Red-conjugated) antibodies.
C and D, paired phase contrast of each image is
shown. E, a different anti-ABCA3 (rabbit anti-human) was
used to immunoblot rat (lane 1) and human (fetal lung
explant, DCI-treated) (lane 2) samples from purified
lamellar bodies. Binding was visualized by goat anti-rabbit horseradish
peroxidase-conjugated secondary antibody. A band at 180 kDa
(arrow) is apparent in the human sample. Bars,
C, 10 µm; D, 2.5 µm.
|
|
Post-translational Targeting of hABCA3 in A549 and H441
Cells--
The deduced protein structure from the human cDNA
sequence and comparisons to other ABC transporters (30) as well as the data provided above indicate that ABCA3 is likely to be a transmembrane protein. To examine the subcellular localization of ABCA3, A549 and
H441 cells were transiently transfected with cDNA encoding hABCA3/enhanced green fluorescent protein (EGFP) fusion proteins. The
transfected fusion proteins were consistently localized to cytoplasmic
vesicles when expressed by either A549 or H441 cells (Fig.
9, A and E). In
contrast, cells transfected with the EGFPN1 plasmid alone showed a
diffused appearance (Fig. 9, B and F). At higher
magnification, ABCA3/EGFP fluorescence in transfected A549 cells had a
ring-like appearance (Fig. 9A, inset) suggesting localization of ABCA3/EGFP to vesicle membranes.

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 9.
Expression of EGFP-tagged ABCA3 by A549 and
H441 cells. A549 (A-D) and H441 (E-H)
cells grown on coverslips were transiently transfected either with
ABCA3/EGFP-N1 (A and E) or EGFP-N1 (control)
(B and F) plasmids using the FuGENE 6 transfection system. Images of EGFP expression were acquired 60 h
after transfection by fluorescence microscopy (A,
B, E, and F). Paired phase contrast
images of corresponding figures are shown (C, D,
G, and H). Bars, 10 µm.
|
|
 |
DISCUSSION |
The lamellar bodies of ATII cells play a central role in
surfactant lipid and protein homeostasis in the lung. As a step toward understanding the nature and assembly of lamellar bodies, we identified previously several monoclonal antibodies that react specifically to the
limiting membrane of lamellar bodies. One of these antibodies was shown
to recognize LBM180, a 180-kDa protein in the limiting membrane of
lamellar bodies of rat lung (25). By using immunoprecipitation and
tandem array mass spectrometry, we identified LBM180 to be ABCA3, a
protein that belongs to a family of transporters that are involved in
active transport of various substrates across cell and organelle
membranes. By using an antibody raised against a synthetic peptide
corresponding to 13 amino acid residues of human ABCA3, ABCA3 was
recently shown to be a lamellar body protein of ATII cells (34). Lung
tissue had the highest expression of ABCA3 RNA of the dozen rat tissues
examined (Fig. 4) similar to that found previously for human tissues
(32). Transcripts of ABCA3 were also abundantly expressed in rat
stomach, intestine, and kidney suggesting that the function of ABCA3
may not be exclusive to ATII cells.
Comparison between human, rat, and mouse RT-PCR products showed a
highly conserved 82-amino acid deduced sequence that corresponds to the
amino-terminal region of ABCA3 (Fig. 3). The 82-amino acid sequence
used for comparison represents only ~5% of the total hABCA3 protein.
However, this region is not within any of the conserved domains of the
ABC transporters, e.g. the Walker ATP-binding motifs. This
consideration supports the likelihood of high homology of ABCA3 between
species. High homology between mouse and rat amino acid sequences (91%
identical and 98% conserved) could explain why mAb 3C9 reacted with
mouse lamellar bodies (Fig. 7) even though this antibody was originally
generated from purified lamellar body membrane proteins of rat lung
(25).
Our study shows that the ABCA3 gene was strongly
up-regulated during human and rat fetal lung development. The highest
expression of the transcript in the rat lung was observed 1 or 2 days
before birth (Fig. 5) at the same time as the induction of the message for surfactant-associated proteins, consistent with involvement of
ABCA3 in development of ATII cells and the surfactant system. Expression of ABCA3 mRNA by ATII progenitor cells isolated from human fetal lung was highly induced (>35-fold) by DCI treatment, and
ABCA3 protein localizes to newly formed lamellar bodies in these cells.
In this cell culture system, however, there is a coordinated induction
of lamellar body constituents (SP-B, -C, and phospholipids) and ABCA3
of the limiting membrane, further supporting a role for ABCA3 in
lamellar body genesis. These findings are in agreement with earlier
studies in other systems that have shown temporal correlations between
developmental increases in various enzymes involved in synthesis of
fatty acids and surfactant proteins (55-59) and also demonstrated the
glucocorticoid-dependent appearance of lamellar bodies and
mRNAs of surfactant proteins (60, 61). Numerous other studies have
also shown surfactant phospholipid (49, 50, 53, 62) and protein (50,
51, 60, 63) production is developmentally regulated during gestation and reaches maximal levels prior to birth. Endogenous hormones, such as
glucocorticoids, appear to be involved in the regulation of this
phenomenon (3, 57, 64). The decrease in ABCA3 mRNA content observed
at postnatal day 7 (Fig. 5) is compatible with hormonal regulation of
expression because the lowest plasma concentration of total
corticosterone is found on days 6-12 in rats (65).
The data presented here and by Yamano et al. (34) place
ABCA3 in the lamellar body membrane of ATII cells. The sorting of ABCA3
was mimicked by the ABCA3/EGFP fusion construct, which was sorted to
vesicular membranes in A549 cells (Fig. 9). A549 cells were originally
derived from a human lung adenocarcinoma, and in early passages they
expressed lamellar bodies (66, 67). Although most of the lung
epithelial phenotype has been lost in these cells, a fraction of late
passage A549 cells still show vesicles with a morphology similar to
lamellar bodies which may account for sorting of ABCA3/EGFP in the
distinctive ring-like pattern observed (Fig. 9, inset).
The antibodies against hABCA3 label ATII cell vesicles in a ring-like
manner by immunofluorescence (Fig. 8B) (34). Anti-hABCA3 antibodies also recognize either a 180-kDa protein (Fig. 8E,
lane 2) or 150-kDa protein, Yamano et al. (34),
in Western blots. These data are comparable with the protein
characteristics demonstrated by using mAb 3C9 (Figs. 1C,
lane 2, and 8A) in rat ATII cells. The difference
in apparent molecular weights observed here and by Yamano et
al. (34) may be explained by the difference in electrophoresis
procedures used in the two studies or by differences in the epitopes
recognized by the two antibodies. Because mAb 3C9 and our anti-hABCA3
do not bind to immunoblots after the samples are boiled, our samples
were incubated in SDS at room temperature. This altered procedure could
have resulted in a different apparent molecular weight for ABCA3.
Alternatively, our antibody may recognize the full-length ABCA3, with a
predicted molecular mass of 191 kDa, whereas the Yamano et
al. (34) antibody recognizes a shorter, post-translationally
modified protein.
What role does ABCA3 play in the biology of ATII cells? When hABCA3 was
originally cloned, it was classified as a member of the ABCA subfamily
due to its high homology to ABCA1 (36% identity and 54% conserved at
the amino acid level) (32, 33). ABCA1 is critically involved in
cellular trafficking of cholesterol and choline phospholipids (68).
Tangier disease, characterized by the absence of plasma high density
lipoprotein and defective removal of cellular cholesterol and
phospholipids, is due to a mutation in ABCA1 (69). The mouse ABCA1 (70)
and Caenorhabditis elegans protein, Ced-7 (71) (a homologue
of ABCA3 and ABCA1), facilitate apoptotic cell engulfment and dead-cell
ingestion, respectively, by a mechanism that involves the transbilayer
movement of phospholipids (72). Several other ABC transporters within the ABCA subfamily are also believed to be involved in lipid transport. ABCA4 appears to mediate retinol transport, by flipping modified phosphatidylethanolamine to the outer leaflet of the cell membrane (30,
73). ABCA2, ABCA7, and ABCA8, like ABCA1, are up-regulated in a
sterol-dependent mechanism (35, 36).
A number of other ABC transporters, although not in the ABCA subfamily,
have been implicated in mediating lipid transport across membranes.
ABCB4 (MDR3), a member of the multidrug transporter subfamily, is a
specialized translocator required for secretion of phosphatidylcholine
(PC) into bile (74). MDR2 (the murine homologue of MDR3) knockout mice
are completely unable to secrete PC, which results in damage of the
canalicular membrane of hepatocytes and small bile ducts (74).
Recently, familial MDR3 deficiency in human was identified and is
characterized by intrahepatic cholestasis with high
-glutamyl
transpeptidase, causing severe liver disease (75). Two members of the
ABCG subfamily, ABCG5 and ABCG8, also have been implicated in a genetic
form of hyperlipidemia caused by impaired secretion of sterol and
related compounds to the intestinal lumen and bile (68). The
peroxisomal ABC transporter is an intracellular membrane transporter
and has been shown to transport fatty acids and metabolites across
peroxisomal membranes (76).
As mentioned earlier, this study and others (34) have localized ABCA3
in lamellar body membranes. We have also reported, from studies using
mAb 3C9, that LBM180 is expressed on the plasma membrane of ATII cells
and is recycled back to lamellar bodies (77). The site of action of
ABCA3 could therefore be either at the cell surface or in membranes of
intracellular organelles including lamellar bodies or both.
The most likely possibility for function of this protein is, therefore,
that ABCA3 transports lipid across the cell or lamellar body limiting
membrane. Specifically, because the lipid content of lamellar bodies is
highly enriched in PC, ABCA3 may either transport PC into lamellar
bodies or transport other lipids such as phosphatidylserine,
phosphatidylethanolamine, sphingomyelin, or sphingolipids out of
lamellar bodies. Either mechanism would have the capacity to enrich the
PC content of lamellar bodies.
 |
ACKNOWLEDGEMENTS |
We thank Roland Annan (Smith Kline & French Laboratories) for the invaluable contribution to the process of
identification of ABCA3 by mass spectrometry; Chandra Dodia and Dr.
Jain-Qin Tao for their technical assistance; and David W. Haddaway
(Chesapeake, VA) for editorial assistance.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grants HL-19737 (to H. S., A. B. F., and P. L. B.) and
HL-53566 (to S. I. F.) and by the Gisela and Dennis Alter Endowed
Chair in Neonatology (to P. L. B. and L. W. G.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Recipient of National Research Service Award T32HL-07748. Present
address: Pulmonary and Critical Care Division, University of
Pennsylvania School of Medicine, 841 BRB II/III Bldg.,
421 Curie Blvd., Philadelphia, PA 19104-6061.
¶
Recipient of National Research Service Award T32HL-07748.
Present address: Division of Neonatology, Rm. 416, Dept. of Pediatrics, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-4399.
**
To whom correspondence should be addressed: Dept. of Physiology,
University of Pennsylvania School of Medicine, 3700 Hamilton Walk,
Richards Bldg., Philadelphia, PA 19104-6085. Tel.: 215-573-2757; Fax:
215-898-2653; E-mail: shuman@mail.med.upenn.edu.
Published, JBC Papers in Press, April 8, 2002, DOI 10.1074/jbc.M201812200
 |
ABBREVIATIONS |
The abbreviations used are:
ATII, alveolar type
II;
ABC, ATP binding cassette;
MDR, multidrug-resistant;
SP, surfactant
protein;
RT, reverse transcription;
Dex, dexamethasone;
IBMX, isobutylmethylxanthine;
EGFP, enhanced green fluorescent protein;
PC, phosphatidylcholine;
mAb, monoclonal antibody.
 |
REFERENCES |
| 1.
|
Wright, J. R.,
and Dobbs, L. G.
(1991)
Annu. Rev. Physiol.
53,
395-414[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Dobbs, L. G.
(1994)
Am. J. Respir. Crit. Care Med.
150,
S31-S32[Medline]
[Order article via Infotrieve]
|
| 3.
|
Rooney, S. A.,
Young, S. L.,
and Mendelson, C. R.
(1994)
FASEB J.
8,
957-967[Abstract]
|
| 4.
|
Batenburg, J. J.,
and Haagsman, H. P.
(1998)
Prog. Lipid Res.
37,
235-276[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Ryan, U. S.,
Ryan, J. W.,
and Smith, D. S.
(1975)
Tissue & Cell
7,
587-599[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Crystal, R. G.,
West, J. B.,
Weibel, E. R.,
and Barnes, P. J.
(1999)
in
The Lung
(Crystal, R. G., ed)
, p. 564, Lippincott-Raven, Philadelphia
|
| 7.
|
Young, S. L.,
Kremers, S. A.,
Apple, J. S.,
Crapo, J. D.,
and Brumley, G. W.
(1981)
J. Appl. Physiol.
51,
248-253[Abstract/Free Full Text]
|
| 8.
|
Hallman, M.,
Epstein, B. L.,
and Gluck, L.
(1981)
J. Clin. Invest.
68,
742-751[Medline]
[Order article via Infotrieve]
|
| 9.
|
Chander, A.,
Reicherter, J.,
and Fisher, A. B.
(1987)
J. Clin. Invest.
79,
1133-1138[Medline]
[Order article via Infotrieve]
|
| 10.
|
Fisher, A. B.,
and Chander, A.
(1985)
Annu. Rev. Physiol.
47,
789-802[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Young, S. L.,
Wright, J. R.,
and Clements, J. A.
(1989)
J. Appl. Physiol.
66,
1336-1342[Abstract/Free Full Text]
|
| 12.
|
Young, S. L.,
Fram, E. K.,
Larson, E.,
and Wright, J. R.
(1993)
Am. J. Physiol.
265,
L19-L26[Medline]
[Order article via Infotrieve]
|
| 13.
|
Voorhout, W. F.,
Veenendaal, T.,
Haagsman, H. P.,
Weaver, T. E.,
Whitsett, J. A.,
van Golde, L. M.,
and Geuze, H. J.
(1992)
Am. J. Physiol.
263,
L479-L486[Medline]
[Order article via Infotrieve]
|
| 14.
|
Beers, M. F.,
Lomax, C. A.,
and Russo, S. J.
(1998)
J. Biol. Chem.
273,
15287-15293[Abstract/Free Full Text]
|
| 15.
|
Ryan, R. M.,
Morris, R. E.,
Rice, W. R.,
Ciraolo, G.,
and Whitsett, J. A.
(1989)
J. Histochem. Cytochem.
37,
429-440[Abstract]
|
| 16.
|
Chevalier, G.,
and Collet, A. J.
(1972)
Anat. Rec.
174,
289-310[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Jobe, A.,
Ikegami, M.,
Sarton-Miller, I.,
Jones, S.,
and Yu, G.
(1981)
Biochim. Biophys. Acta
666,
47-57[Medline]
[Order article via Infotrieve]
|
| 18.
|
Magoon, M. W.,
Wright, J. R.,
Baritussio, A.,
Williams, M. C.,
Goerke, J.,
Benson, B. J.,
Hamilton, R. L.,
and Clements, J. A.
(1983)
Biochim. Biophys. Acta
750,
18-31[Medline]
[Order article via Infotrieve]
|
| 19.
|
Muller, W. J.,
Zen, K.,
Fisher, A. B.,
and Shuman, H.
(1995)
Am. J. Physiol.
269,
L11-L19[Medline]
[Order article via Infotrieve]
|
| 20.
|
deMello, D. E.,
Heyman, S.,
Phelps, D. S.,
Hamvas, A.,
Nogee, L.,
Cole, S.,
and Colten, H. R.
(1994)
Am. J. Respir. Cell Mol. Biol.
11,
230-239[Abstract]
|
| 21.
|
deMello, D. E.,
Nogee, L. M.,
Heyman, S.,
Krous, H. F.,
Hussain, M.,
Merritt, T. A.,
Hsueh, W.,
Haas, J. E.,
Heidelberger, K.,
and Schumacher, R.
(1994)
J. Pediatr.
125,
43-50[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Clark, J. C.,
Wert, S. E.,
Bachurski, C. J.,
Stahlman, M. T.,
Stripp, B. R.,
Weaver, T. E.,
and Whitsett, J. A.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
7794-7798[Abstract/Free Full Text]
|
| 23.
|
Cutz, E.,
Wert, S. E.,
Nogee, L. M.,
and Moore, A. M.
(2000)
Am. J. Respir. Crit. Care Med.
161,
608-614[Abstract/Free Full Text]
|
| 24.
|
Tryka, A. F.,
Wert, S. E.,
Mazursky, J. E.,
Arrington, R. W.,
and Nogee, L. M.
(2000)
Pediatr. Dev. Pathol.
3,
335-345[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Zen, K.,
Notarfrancesco, K.,
Oorschot, V.,
Slot, J. W.,
Fisher, A. B.,
and Shuman, H.
(1998)
Am. J. Physiol.
275,
L172-L183[Medline]
[Order article via Infotrieve]
|
| 26.
|
Dean, M.,
Hamon, Y.,
and Chimini, G.
(2001)
J. Lipid Res.
42,
1007-1017[Abstract/Free Full Text]
|
| 27.
|
Higgins, C. F.
(1992)
Annu. Rev. Cell Biol.
8,
67-113[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
| Childs, S., and Ling, V. (1994) Important Adv. Oncol.
21-36
|
| 29.
|
Dean, M.,
and Allikmets, R.
(1995)
Curr. Opin. Genet. & Dev.
5,
779-785[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Klein, I.,
Sarkadi, B.,
and Varadi, A.
(1999)
Biochim. Biophys. Acta
1461,
237-262[Medline]
[Order article via Infotrieve]
|
| 31.
|
Schriml, L. M.,
and Dean, M.
(2000)
Genomics
64,
24-31[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Klugbauer, N.,
and Hofmann, F.
(1996)
FEBS Lett.
391,
61-65[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Connors, T. D.,
Van Raay, T. J.,
Petry, L. R.,
Klinger, K. W.,
Landes, G. M.,
and Burn, T. C.
(1997)
Genomics
39,
231-234[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Yamano, G.,
Funahashi, H.,
Kawanami, O.,
Zhao, L. X.,
Ban, N.,
Uchida, Y.,
Morohoshi, T.,
Ogawa, J.,
Shioda, S.,
and Inagaki, N.
(2001)
FEBS Lett.
508,
221-225[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Borst, P.,
Zelcer, N.,
and van Helvoort, A.
(2000)
Biochim. Biophys. Acta
1486,
128-144[Medline]
[Order article via Infotrieve]
|
| 36.
|
Kaminski, W. E.,
Orso, E.,
Diederich, W.,
Klucken, J.,
Drobnik, W.,
and Schmitz, G.
(2000)
Biochem. Biophys. Res. Commun.
273,
532-538[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Mulugeta, S.,
Annan, R. S.,
Notarfancesco, K.,
Fisher, A. B.,
and Shuman, H.
(2000)
Am. J. Respir. Crit. Care Med.
161,
43
|
| 38.
|
Mulugeta, S.,
Gonzales, L. W.,
Ballard, P. L.,
Fisher, A. B.,
and Shuman, H.
(2001)
FASEB J.
15,
A496
|
| 39.
|
Robinson, J. M.,
and Vandre, D. D.
(2001)
Histochem. Cell Biol.
116,
119-130[Medline]
[Order article via Infotrieve]
|
| 40.
|
Wagle, S.,
Bui, A.,
Ballard, P. L.,
Shuman, H.,
Gonzales, J.,
and Gonzales, L. W.
(1999)
Am. J. Physiol.
277,
L381-L390[Medline]
[Order article via Infotrieve]
|
| 41.
|
Gonzales, L. W.,
Ballard, P. L.,
and Gonzales, J.
(1994)
Biochim. Biophys. Acta
1215,
49-58[Medline]
[Order article via Infotrieve]
|
| 42.
|
Dobbs, L. G.,
Gonzalez, R.,
and Williams, M. C.
(1986)
Am. Rev. Respir. Dis.
134,
141[Medline]
[Order article via Infotrieve]
|
| 43.
|
Alcorn, J. L.,
Smith, M. E.,
Smith, J. F.,
Margraf, L. R.,
and Mendelson, C. R.
(1997)
Am. J. Respir. Cell Mol. Biol.
17,
672-682[Abstract/Free Full Text]
|
| 44.
|
Gonzales, L. W.,
Angampalli, S.,
Guttentag, S. H.,
Beers, M. F.,
Feinstein, S. I.,
Matlapudi, A.,
and Ballard, P. L.
(2001)
Pediatr. Pathol. Mol. Med.
20,
387-412[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Gonzales, L. W.,
and Ballard, P. L.
(2001)
Pediatr. Res
49,
262A
|
| 46.
|
Chander, A.,
Dodia, C. R.,
Gil, J.,
and Fisher, A. B.
(1983)
Biochim. Biophys. Acta
753,
119-129[Medline]
[Order article via Infotrieve]
|
| 47.
|
Xie, J.,
Drumm, M. L., Ma, J.,
and Davis, P. B.
(1995)
J. Biol. Chem.
270,
28084-28091[Abstract/Free Full Text]
|
| 48.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
van Golde, L. M.
(1995)
Biol. Neonate
67 Suppl. 1,
2-17[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Ogasawara, Y.,
Kuroki, Y.,
Shiratori, M.,
Shimizu, H.,
Miyamura, K.,
and Akino, T.
(1991)
Biochim. Biophys. Acta
1083,
252-256[Medline]
[Order article via Infotrieve]
|
| 51.
|
Mendelson, C. R.,
Acarregui, M. J.,
Odom, M. J.,
and Boggaram, V.
(1991)
J. Dev. Physiol. (Eynsham)
15,
61-69
|
| 52.
|
Ballard, P. L.
(1989)
Endocr. Rev.< |